Aclaris Therapeutics
(NASDAQ) ACRS
Aclaris Therapeutics Financials at a Glance
Market Cap
$766.76MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$8.37M
Net Income (TTM)
-$69.66M
EPS (TTM)
-$0.56
P/E Ratio
-9.80
Dividend
$0.00
Beta (Volatility)
1.11 (Average)
Dividend
$0.00
Beta (Volatility)
1.11 (Average)
Price
$5.74
Volume
18,911
Open
$5.43
Price
$5.74
Volume
18,911
Open
$5.43
Previous Close
$5.49
Daily Range
$5.39 - $5.75
52-Week Range
$1.44 - $5.75
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
1.11 (Average)
Price
$5.74
Volume
18,911
Open
$5.43
Previous Close
$5.49
Daily Range
$5.39 - $5.75
52-Week Range
$1.44 - $5.75
Estimated Earnings Date
Aug 6, 2026
ACRS News
The Best IPOs of 2015
ACRS: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Aclaris Therapeutics
Industry
Pharmaceuticals
Sector
Health CareEmployees
73
CEO
Neal S. Walker, PhD, MBA
Website
www.aclaristx.comHeadquarters
Wayne, PA 19087, US
ACRS Financials
Key Financial Metrics (TTM)
Gross Margin
76.34%
Operating Margin
-961.91%
Net Income Margin
-832.58%
Return on Equity
-55.89%
Return on Capital
-72.60%
Return on Assets
-35.06%
Earnings Yield
-10.20%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$766.76MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
139.66M
Volume
18.91K
Avg. Volume
1.54M
Financials (TTM)
Gross Profit
$6.39M
Operating Income
-$80.48M
EBITDA
-$70.61M
Operating Cash Flow
-$52.21M
Capital Expenditure
-$81.00K
Free Cash Flow
-$52.27M
Cash & ST Invst.
$105.42M
Total Debt
$1.99M
Aclaris Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$2.00M
+37.2%
Gross Profit
$1.60M
+68.7%
Gross Margin
80.21%
N/A
Market Cap
$766.76MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$12.57M
N/A
Employees
61
N/A
Net Income
-$19.82M
-31.4%
EBITDA
-$19.72M
-11.7%
Quarterly Fundamentals
Total Cash
$105.42M
+0.1%
Total Debt
$1.99M
-20.1%
Accounts Receivable
$4.81M
+1825.6%
Inventory
$0.00
N/A
Long Term Debt
$1.42M
-28.7%
Short Term Debt
$569.00K
+14.3%
Return on Assets
-35.06%
N/A
Return on Invested Capital
-46.97%
N/A
Free Cash Flow
-$18.15M
-30.3%
Operating Cash Flow
-$18.15M
-39.0%